Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...

Goldman Sachs analyst Davin Thillainathan initiated coverage of CSL (CSLLY) with a Buy rating and A$325.40 price target The firm believes the company’s investments in its immunoglobulin ...

Beyond logos, create business cards, social media kits, favicons, and more. Download high-resolution PNG, JPEG, and vector files, and get brand guidelines for fonts and colors. Make unlimited changes ...

Research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines.

Learn More CSL Ltd (ASX: CSL) stock had an underwhelming year in 2024. During the 12 months, the biotechnology giant's shares traded relatively flat and underperformed the market. While this is ...

Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The company’s shares closed yesterday at $167.11. Discover ...

Learn More Now could be the time to pounce on CSL Ltd (ASX: CSL) shares. That's the view of analysts at Goldman Sachs, which have just initiated coverage on the company. CSL is a global ...

For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.